Robust Annual Growth in the Renal Cell Carcinoma Drug Market Will be Driven by the Uptake of GlaxoSmithKline's Votrient/Patorma and the Launches of Premium-Priced Emerging Therapies
Advertisement
In 2009, Angiogenesis Inhibitors Captured More Than Three-Quarters of the Renal Cell Carcinoma Drug Market, According to Findings from Decision Resources